Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Abstract Triple‐class‐refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low‐dose dexamethasone (Sel‐dex) demonstrated a 26.2% overall respons...

Full description

Bibliographic Details
Main Authors: Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A. Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David Siegel, William Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin Shah, Sharon Shacham, Sagar Lonial
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:eJHaem
Subjects:
multiple myeloma
selective inhibitor of nuclear export
selinexor
triple‐class‐refractory multiple myeloma
Online Access:https://doi.org/10.1002/jha2.120

Internet

https://doi.org/10.1002/jha2.120

Similar Items